Should You Buy BioAtla, Inc. Stock in 2026?
According to the CirclFi Deep Alpha Valuation Engine, BioAtla, Inc. (BCAB) scores 4.6/10 on our Quality of Company framework, indicating mixed operational fundamentals. At the current price of $3.70, our multi-model valuation analyzes whether the market has already discounted these weaknesses.
The short answer: 3 of 5 CirclFi valuation models project upside for BioAtla, Inc. (BCAB) at $3.70 — the model consensus leans bullish, with a Quality Score of 4.6/10 and Value-Trap risk of 30/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.
Investment Thesis
The Bull Case
Target: $15.55 (+320.4% upside)
- According to the CirclFi Deep Alpha Valuation Engine, 3 of 5 models identify upside from $3.70 to a composite fair value of $6.10, indicating the market hasn't fully priced in BioAtla, Inc.'s earnings power.
- According to the CirclFi Deep Alpha Valuation Engine, the Bayesian DCF model targets a fair value of $15.55 (+320.4%), anchoring the bull case with a methodology that incorporates probability-weighted cash flow scenarios.
The Bear Case
Target: $0.19 (-94.8%)
- According to the CirclFi Quality of Company (QOC) framework, BioAtla, Inc.'s score of 4.6/10 signals fundamental weaknesses that could undermine the investment thesis.
- According to the CirclFi Deep Alpha Valuation Engine, the ML Residual Income model sees the stock as overvalued with a fair value of $0.19 (-94.8%), suggesting that the market price embeds overly optimistic growth assumptions.
- According to the CirclFi Deep Alpha Valuation Engine, the wide model spread of +415.2% reflects fundamental divergence on key assumptions (growth, cost of capital) depending on the methodology.
The Bottom Line
BioAtla, Inc. leans positive in our analysis — 3/5 models bullish, composite fair value of $6.10 vs. $3.70, QOC 4.6/10. The case is constructive but not overwhelming, and the 2 dissenting models shouldn't be dismissed. Position sizing should reflect this moderate conviction level.
These are quantitative model outputs, not investment recommendations. BioAtla, Inc.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →
Frequently Asked Questions
Should I buy BCAB stock right now?
Based on CirclFi's multi-model analysis, 3 of 5 models see upside for BCAB at $3.70. The majority of models suggest the stock trades below fair value, but investors should weigh this against the Quality Score of 4.6/10 and individual risk tolerance. This is not a buy recommendation — see our full disclaimer.
What are the biggest risks of investing in BioAtla, Inc.?
Key risks include: a below-average Quality Score of 4.6/10, indicating fundamental weakness; limited model coverage (5/13 active), reducing analytical confidence; wide model disagreement (7960% spread), signaling high uncertainty; general market and sector-specific risks affecting Biological Products, (No Diagnostic Substances) companies. Always diversify and consult a financial advisor.
How does BCAB compare to its competitors?
Among Biological Products, (No Diagnostic Substances) peers, BCAB holds a Quality Score of 4.6/10. Comparable companies include EXEL (QOC 10.0), HALO (QOC 10.0), NBIX (QOC 10.0). The relative ranking helps investors identify whether BCAB offers better fundamental quality than alternatives in the same sector.
Is BCAB a good long-term investment?
Long-term investment potential depends on fundamental quality and sustainable competitive advantages. BCAB's Quality Score of 4.6/10 raises concerns about long-term viability without significant operational improvements. Check our full data page for all 13 model estimates.
What price should I buy BCAB at?
CirclFi does not provide target buy prices or price alerts. However, our 5 active models produce fair value estimates ranging from $0.19 to $15.55. At $3.70, the stock trades within the range of model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.
Want the complete picture?
See all 13 model estimates, confidence scores, and the full valuation table for BCAB.
Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →
Buy with Gumroad